Navigation Links
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
Date:4/20/2011

SAN FRANCISCO and SEOUL, South Korea, April 20, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.  The data were reported in the journal Molecular Therapy.

Patients enrolled in a Phase 2 clinical trial for hepatocellular carcinoma (HCC) received three intratumoral administrations of JX-594.  A subset of three patients subsequently received sorafenib, the current standard of care for HCC and the only approved systemic therapy for this indication to date.  All three of these patients exhibited rapid and marked tumor necrosis as quantitated by serial dynamic MRI imaging; all patients had both Choi (necrotic) and modified Response Evaluation Criteria in Solid Tumor (mRECIST) type responses.  The responses were rapid—as early as 2.5 weeks after sorafenib initiation—and occurred in both JX-594-injected and non-injected tumors.  Notably, similar responses were not seen in HCC patients treated with sorafenib alone at the same institutions (zero of 15 patients). The treatment regimen was well tolerated in each of the patients, and sorafenib toxicities were consistent with the documented historical profile. The JX-594-sorafenib combination regimen is currently being further investigated in another Phase 2 trial.

"Given the strength of the clinical and preclinical data we have observed from our JX-594 trials in liver cancer, we are planning further clinical trials of JX-594 as a single agent and in combination with VEGFR inhibitors.  TRAVERSE, our planned randomized Phase 2b clinical tr
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... conducting this study is to provide an overview ... global market for protein drugs/therapeutics. The key objective ... direction of protein drugs as an important tool ... report explores present and future strategies within the ...
(Date:9/30/2014)... 30, 2014  Decision Resources Group finds that the ... , China , India , ... strong rate through 2023. Dental implant procedure volumes will grow as ... rises. Other key findings from Decision Resources Group,s coverage ... , Dental implant penetration: Penetration of dental implants ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... dengue virus Monday with 56 fresh cases being admitted to ... Delhi government called an// urgent meeting to review the situation. ... Institute of Medical Sciences (AIIMS) reported 41, taking the total ... 941 infected with the mosquito-borne virus, around 579 are residents ...
... Whenever one has to watch shaky images recorded by an ... ever consider how the brain //restores an almost continuous shaky ... back and forth taking also into consideration our bodies which ... ,Researchers at the Salk Institute for Biological Studies ...
... come up with novel methods to study 'better than nature' ... in maintaining a healthy cardiovascular system without the typical side ... presented at the Annual Meeting of the American College of ... high allicin garlic macerate can be delivered to the body ...
... extended to 2015. , The commission had been assigned the task ... needs of the mentally ill and was set to finish next ... response to the Mason Inquiry into Mental Health Services. They were ... has been trying to meet. , ,According to Health ...
... tide waits for no man and none other than ‘gen–present’ ... the ebb and flow of waters continue unabated, people are ... tomorrows. Living on the edge, seeking newer excitement propelled by ... obsession. Today, ‘failure’ is unacceptable - a mute ...
... of over 5,000 lbs. of ground beef as a precautionary ... that was processed and/or handled by the firm. ... that we have a negative test on the beef in ... proceed." ,It has been estimated that the 5,200 lbs. ...
Cached Medicine News:Health News:56 New Dengue Cases; Delhi Govt. to Review Situation 2Health News:Perception Stabilized – Thanks to Your Brains 2Health News:Perception Stabilized – Thanks to Your Brains 3Health News:New Garlic Product Mimics Garlic to Perfection 2Health News:Mental Health: Mind at Peace or in Pieces? 2Health News:Mental Health: Mind at Peace or in Pieces? 3Health News:Mental Health: Mind at Peace or in Pieces? 4Health News:Precautionary Recall of Beef over E.coli Contamination Concerns 2
The clarity and performance of glass with shatterproof safety of plastic....
Accurate and easy hematocrits in two minutes. Choose glass or easy to read SafeCrit plastic tubes, plain or heparinized. These tubes feature rapid capillary action and have a two-year shelf life. For...
... In the Innova™ 4100, the ... X-ray system for angiographic imaging, ... piece, non tiled Digital Detector ... reliably provide high resolution imaging ...
... is a bench-top fully automated random ... host of features usually only seen ... has the capacity to perform up ... ISEs, and offers primary tube sampling, ...
Medicine Products: